Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leflunomide in High-Risk Smoldering Multiple Myeloma
NCT05014646Phase 2Active, not recruiting
- Sponsor
- City of Hope
- Start
- Mar 2022
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of leflunomide in smoldering multiple myeloma (SMM), sponsored by City of Hope. Started Mar 2022; status: active, not recruiting.
02
Drugs
leflunomide
03
Conditions
smoldering multiple myeloma (SMM)
Beyond the preview
Go deeper on NCT05014646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05014646.